The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity: Clinical article
Abstract
Object: Despite improvements in the medical and surgical management of patients with glioblastoma, tumor recurrence remains inevitable. For recurrent glioblastoma, however, the clinical value of a second resection remains uncertain. Specifically, what proportion of contrast-enhancing recurrent glioblastoma tissue must be removed to improve overall survival and what is the neurological cost of incremental resection beyond this threshold? Methods: The authors identified 170 consecutive patients with recurrent supratentorial glioblastomas treated at the Barrow Neurological Institute from 2001 to 2011. All patients previously had a de novo glioblastoma and following their initial resection received standard temozolomide and fractionated radiotherapy. Results: The mean clinical follow-up was 22.6 months and no patient was lost to follow-up. At the time of recurrence, the median preoperative tumor volume was 26.1 cm 3. Following re-resection, median postoperative tumor volume was 3.1 cm 3, equating to an 87.4% extent of resection (EOR). The median overall survival was 19.0 months, with a median progression-free survival following re-resection of 5.2 months. Using Cox proportional hazards analysis, the variables of age, Karnofsky Performance Scale (KPS) score, and EOR were predictive of survival following repeat resection (p = 0.0001). Interestingly, a significant survival advantage was noted with as little as 80% EOR. Recursive partitioning analysis validated these findings and provided additional risk stratification at the highest levels of EOR. Overall, at 7 days after surgery, a deterioration in the NIH stroke scale score by 1 point or more was observed in 39.1% of patients with EOR ≥ 80% as compared with 16.7% for those with EOR < 80% (p = 0.0049). This disparity in neurological morbidity, however, did not endure beyond 30 days postoperatively (p = 0.1279). Conclusions: For recurrent glioblastomas, an improvement in overall survival can be attained beyond an 80% EOR. This survival benefit must be balanced against the risk of neurological morbidity, which does increase with more aggressive cytoreduction, but only in the early postoperative period. Interestingly, this putative EOR threshold closely approximates that reported for newly diagnosed glioblastomas, suggesting that for a subset of patients, the survival benefit of microsurgical resection does not diminish despite biological progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
Making sense of cronbach’s alpha.
Tavakol, M., & Dennick, R. (2011) · International Journal of Medical Education · doi:10.5116/ijme.4dfb.8dfd · Cited by 15,126
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Measurements of acute cerebral infarction: a clinical examination scale.
Brott, T., Adams, H. P., Olinger, C. P., Marler, J. R., Barsan, W. G., Biller, J., Spilker, J., Holleran, R., Eberle, R., & Hertzberg, V (1989) · Stroke · doi:10.1161/01.str.20.7.864 · Cited by 5,911
QUANTIFYING TEST-RETEST RELIABILITY USING THE INTRACLASS CORRELATION COEFFICIENT AND THE SEM
WEIR, J. P. (2005) · Journal of Strength and Conditioning Research · doi:10.1519/00124278-200502000-00038 · Cited by 4,842
The Design and Analysis of Clinical Experiments
Fleiss, J. L. (1999) · Wiley eBooks · doi:10.1002/9781118032923 · Cited by 4,819
The handbook of psychological testing
(1993) · Choice Reviews Online · doi:10.5860/choice.31-1802 · Cited by 3,534
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
The Design and Analysis of Clinical Experiments.
Hills, M., & Fleiss, J. L. (1987) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2982050 · Cited by 3,261
Cited by
Survival in glioblastoma: a review on the impact of treatment modalities
Delgado-López, P. D., & Corrales-García, E. M. (2016) · Clinical and Translational Oncology · doi:10.1007/s12094-016-1497-x · Cited by 659
Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials
Ellingson, B. M., Wen, P. Y., & Cloughesy, T. F. (2017) · Neurotherapeutics · doi:10.1007/s13311-016-0507-6 · Cited by 476
Maximizing safe resection of low- and high-grade glioma
Hervey-Jumper, S. L., & Berger, M. S. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2110-4 · Cited by 471
Surgical oncology for gliomas: the state of the art
Sanai, N., & Berger, M. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.171 · Cited by 332
Self-citationCurrent trends in the surgical management and treatment of adult glioblastoma.
Young, R. M., Jamshidi, A. M., Davis, G., & Sherman, J. H. (2015) · PubMed · doi:10.3978/j.issn.2305-5839.2015.05.10 · Cited by 308
Metadata
- Authors
- Oppenlander, M. E., Wolf, A. B., Snyder, L. A., Bina, R., Wilson, J. R., Coons, S. W., Ashby, L. S., Brachman, D., Nakaji, P., Porter, R. W., Smith, K. A., Spetzler, R. F., & Sanai, N.
- Venue
- Journal of Neurosurgery
- Published
- 2014-04
- Volume
- 120
- Issue
- 4
- Pages
- 846-853
- ISSN
- 0022-3085 (ISSN-L)
- 1933-0693
- OpenAlex
- W1587922612
- Cited by
- 266
- References
- 32
- FWCI
- 12.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity: Clinical article. https://app.cochat.ai/papers/10.3171/2013.12.jns13184
- The paper
- Oppenlander, M. E., Wolf, A. B., Snyder, L. A., Bina, R., Wilson, J. R., Coons, S. W., Ashby, L. S., Brachman, D., Nakaji, P., Porter, R. W., Smith, K. A., Spetzler, R. F., & Sanai, N. (2014). An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity: Clinical article. Journal of Neurosurgery. https://doi.org/10.3171/2013.12.jns13184
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.